期刊文献+

辛伐他汀联合苯那普利治疗糖尿病肾病临床分析 被引量:2

下载PDF
导出
摘要 目的:观察辛伐他汀联合苯那普利治疗糖尿病肾病临床效果。方法:将80例4期DN患者随机分为Ⅰ组(辛伐他汀组),Ⅱ组(苯那普利组),Ⅲ组(联合用药组),Ⅳ组(对照组)。治疗前后分别检测FBG、TG、TC、CR、BUN、UAER。结果:Ⅳ组在治疗前后检测FBG、TG、TC、CR、BUN、UAER,差异无统计学意义(P>0.05);治疗后,Ⅰ组、Ⅱ组、Ⅲ组检测指标中BUN、Cr、UAER、FBG均较治疗前明显下降(P<0.05),Ⅰ组和Ⅲ组检测指标中TG、TC均较治疗前明显下降(P<0.05),并且治疗后Ⅲ组患者的BUN、Cr、UAER、FBG、TG、TC明显低于Ⅰ组和Ⅱ组患者(P<0.05)。结论:辛伐他汀联合苯那普利治疗糖尿病肾病在延缓其进展方面可以发挥各自的优势,起到了协调的作用。
作者 罗干兴
出处 《中国高等医学教育》 2011年第8期141-142,共2页 China Higher Medical Education
  • 相关文献

参考文献3

  • 1孙书珍,汪翼,刘明花,李倩,田永杰,于永慧.苯那普利对糖尿病大鼠肾脏病变保护作用机制的研究[J].山东大学学报(医学版),2006,44(4):404-409. 被引量:4
  • 2SarafidisPA,LasaridisAN,Nilsson PM,et al.The effect of rosiglitazone on urine albumin excretion in patients with type 2 diabetes mellitus and hypertension[J].Am J Hypertens,2005,18(2 Pt1):227-234.
  • 3Heusinger-Ribeiro J,WahabN,Goppest-StruebeM.Lyso-pho-sphatidic acid induced expression of connective tissue growth factor in human renal fibrosis:regulatory role of RhoA and cAMP[J].J Am Soc Nephro,2001,12(7):1853-1861.

二级参考文献12

  • 1Border WA,Noble NA.Evidence that TGF-beta should be a therapeutic target in diabetic nephropathy[J].Kidney Int,1998,54:1 390-1 391.
  • 2Gilbert RE,Cox A,Wu LL,et al.Expression of transforming growth factor-betal and type Ⅳ collagen in the renal tubulointerstitium in experimental diabetes:effects of ACE inhibition[J].Diabetes,1998,47:414-422.
  • 3Nakamura T,Takahashi T,Fukui M,et al.Enalapril attenuates increased gene expression of extracellular matrix components in diabetic rats[J].Am Soc Nephrol,1995,5:1 492-1 497.
  • 4Suzuki D,Miyazaki M,Jinde K,et al.In situ hybridization studies of matrix metalloproteinase-3,tissue inhibitor of metalloproteinase-1 and type Ⅳ collagen in diabetic nephropathy[J].Kidney Int,1997,52(1):111-119.
  • 5Mclennan SV,Martell SK,Yue DK.Effects of mesangium glycation on matrix metalloproteinase activities:possible role in diabetic nephropathy[J].Diabetes,2002,51 (9):2 612-2 618.
  • 6Mclennan SV,Kelly DJ,Cox AJ,et al.Decreased matrix degradation in diabetic nephropathy:effects of ACE inhibition on the expression and activities of matrix metalloproteinases[J].Diabetologia,2002,45(2):268-275.
  • 7Alderson NL,Chachich ME,Frizzel N,et al.Effect of antioxidants and ACE inhibition on chemical modification of proteins and progression of nephropathy in the streptozotocin diabetic rat[J].Diabetologia,2004,47(8):1 385-1 395.
  • 8Allen TJ,Cao Z,Youssef S,et al.Role of angiotensin Ⅱ and bradykinin in experimental diabetic nephropathy.Functional and structural studies[J].Diabetes,1997,46:1 612-1 618.
  • 9Singh R,Alavi N,Singh AK,et al.Role of angiotensin Ⅱ in glucose-induced inhibition of mesangial matrix degradation[J].Diabetes,1999,48:2066-2073.
  • 10Laffel LM,McGill JB,Gans DJ.The beneficial effect of ACE inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria.North America Microalbuminuria Study Group[J].Am Med,1995,99:497-504.

共引文献3

同被引文献10

引证文献2

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部